These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 38443674)

  • 1. Self-reported knowledge of tetrahydrocannabinol and cannabidiol concentration in cannabis products among cancer patients and survivors.
    Goulette M; Schlienz NJ; Case AA; Hansen E; Rivard C; Ashare RL; Goniewicz ML; Bansal-Travers M; Hyland A; Smith DM
    Support Care Cancer; 2024 Mar; 32(4):210. PubMed ID: 38443674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Knowledge of Tetrahydrocannabinol and Cannabidiol Levels Among Cannabis Consumers in the United States and Canada.
    Hammond D; Goodman S
    Cannabis Cannabinoid Res; 2022 Jun; 7(3):345-354. PubMed ID: 33998866
    [No Abstract]   [Full Text] [Related]  

  • 3. Absence of Relevant Thermal Conversion of Cannabidiol to Tetrahydrocannabinol in E-Cigarette Vapor and Low-Tetrahydrocannabinol Cannabis Smoke.
    Hindelang P; Scharinger A; Golombek P; Laible M; Tamosaite S; Walch SG; Lachenmeier DW
    Cannabis Cannabinoid Res; 2022 Oct; 7(5):616-620. PubMed ID: 36169637
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetic Profile of ∆9-Tetrahydrocannabinol, Cannabidiol and Metabolites in Blood following Vaporization and Oral Ingestion of Cannabidiol Products.
    Bergeria CL; Spindle TR; Cone EJ; Sholler D; Goffi E; Mitchell JM; Winecker RE; Bigelow GE; Flegel R; Vandrey R
    J Anal Toxicol; 2022 Jul; 46(6):583-591. PubMed ID: 35438179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. External hair contamination from cannabis and "light cannabis" delivered by smoking and vaping: An in vitro study.
    Giorgetti A; Fais P; Pascali JP; Mohamed S; Rossi F; Garagnani M; Pelletti G
    Drug Test Anal; 2024 Oct; 16(10):1077-1084. PubMed ID: 38145896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabinoid Exposure and Subjective Effects of THC and CBD in Edible Cannabis Products.
    Gibson LP; Mueller RL; Winiger EA; Klawitter J; Sempio C; Williams S; Bryan AD; Bidwell LC; Hutchison KE
    Cannabis Cannabinoid Res; 2024 Feb; 9(1):320-334. PubMed ID: 36378267
    [No Abstract]   [Full Text] [Related]  

  • 7. Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition.
    Arkell TR; Lintzeris N; Kevin RC; Ramaekers JG; Vandrey R; Irwin C; Haber PS; McGregor IS
    Psychopharmacology (Berl); 2019 Sep; 236(9):2713-2724. PubMed ID: 31044290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in prescribed medicinal cannabis use by cannabinoid product composition: Findings from the cannabis as medicine survey 2020 (CAMS-20) Australia-wide study.
    Trevitt BT; Bailey S; Mills L; Arkell TR; Suraev A; McGregor IS; Lintzeris N
    PLoS One; 2024; 19(2):e0297092. PubMed ID: 38354169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta-analysis.
    Freeman TP; Craft S; Wilson J; Stylianou S; ElSohly M; Di Forti M; Lynskey MT
    Addiction; 2021 May; 116(5):1000-1010. PubMed ID: 33160291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial.
    Arkell TR; Vinckenbosch F; Kevin RC; Theunissen EL; McGregor IS; Ramaekers JG
    JAMA; 2020 Dec; 324(21):2177-2186. PubMed ID: 33258890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized, Triple-Blind, Comparator-Controlled Parallel Study Investigating the Pharmacokinetics of Cannabidiol and Tetrahydrocannabinol in a Novel Delivery System, Solutech, in Association with Cannabis Use History.
    Berl V; Hurd YL; Lipshutz BH; Roggen M; Mathur EJ; Evans M
    Cannabis Cannabinoid Res; 2022 Dec; 7(6):777-789. PubMed ID: 35787693
    [No Abstract]   [Full Text] [Related]  

  • 12. A randomised controlled trial of vaporised Δ
    Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
    Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Δ9-Tetrahydrocannabinol and Cannabidiol Time Courses in the Sera of "Light Cannabis" Smokers: Discriminating Light Cannabis Use from Illegal and Medical Cannabis Use.
    Pichini S; Mannocchi G; Berretta P; Zaami S; Pirani F; Pacifici R; Busardò FP
    Ther Drug Monit; 2020 Feb; 42(1):151-156. PubMed ID: 31389860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. THC and CBD concentrations in blood, oral fluid and urine following a single and repeated administration of "light cannabis".
    Pacifici R; Pichini S; Pellegrini M; Rotolo MC; Giorgetti R; Tagliabracci A; Busardò FP; Huestis MA
    Clin Chem Lab Med; 2020 Apr; 58(5):682-689. PubMed ID: 30956228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and Factors Associated With Vaping Cannabidiol Among US Adolescents.
    Dai HD; Subramanian R; Mahroke A; Wang M
    JAMA Netw Open; 2023 Aug; 6(8):e2329167. PubMed ID: 37585202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabidiol and tetrahydrocannabinol concentrations in commercially available CBD E-liquids in Switzerland.
    Grafinger KE; Krönert S; Broillet A; Weinmann W
    Forensic Sci Int; 2020 May; 310():110261. PubMed ID: 32229319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC) and Their Metabolites following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration.
    Sholler DJ; Spindle TR; Cone EJ; Goffi E; Kuntz D; Mitchell JM; Winecker RE; Bigelow GE; Flegel RR; Vandrey R
    J Anal Toxicol; 2022 May; 46(5):494-503. PubMed ID: 34089060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of cannabidiol (CBD) and THC in nonprescription consumer products: Implications for patients and practitioners.
    Miller OS; Elder EJ; Jones KJ; Gidal BE
    Epilepsy Behav; 2022 Feb; 127():108514. PubMed ID: 34998268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Tetrahydrocannabinol Content and Price in Herbal Cannabis Products Offered by Dispensaries in California: A Purview of Consumers/Patients.
    Dobbins M; Rakkar M; Cunnane K; Pennypacker SD; Wagoner KG; Reboussin BA; Romero-Sandoval EA
    Front Public Health; 2022; 10():893009. PubMed ID: 35784239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An assessment of qualitative and quantitative cannabinoids analysis in selected commercially available cannabis oils in Argentina.
    Fernández N; Cappello MG; Quiroga PN
    Forensic Sci Int; 2023 Aug; 349():111762. PubMed ID: 37392612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.